REFRACTORY stock news
This page provides real-time market news, earnings updates, and company announcements related to Refractory Shapes Ltd. (REFRACTORY).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-03-13 06:11 IST
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights
Finviz2026-03-06 13:04:13
QURE Stock Crashes 32% in a Week: Here's What You Should Know
Finviz2026-03-06 16:03:53
Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR
Finviz2026-03-06 20:09:43
Johnson & Johnson, holding the 55th position in trading volume, manages legal resolutions and FDA advancements while recording a 0.32% increase
101 finance2026-03-06 22:39:54
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer
Finviz2026-03-09 11:03:47
Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough
Finviz2026-03-09 11:33:52
The epilepsy treatment drug developed by Xenon Pharmaceuticals (XENE) successfully met the primary endpoint in a pivotal Phase III clinical trial, a breakthrough that drove its share price up by 16.5% in pre-market trading.
老虎证券2026-03-09 12:00:04
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
Finviz2026-03-09 12:03:10
Bristol-Myers Squibb Shares Edge Up 0.56% on Pipeline Progress as 660M Volume Ranks 216th in Market Activity
101 finance2026-03-09 23:30:46
C4 Therapeutics (CCCC) Well Positioned With Cemsidomide Trial Data
Finviz2026-03-10 00:13:04
Johnson & Johnson (JNJ) Announces the FDA Approval of TECVAYLI plus DARZALEX FASPRO
Finviz2026-03-10 08:40:20
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Finviz2026-03-10 11:07:14
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
Finviz2026-03-11 11:03:53
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
Finviz2026-03-11 12:03:49
Northstrive Fund II has sent a letter to the Board of Directors of Bluejay Diagnostics Inc, recommending that they carefully evaluate a potential acquisition opportunity.
老虎证券2026-03-11 13:48:56
BMY Slides to 206th in Trading Volume Amid Clinical Wins and Earnings Pressures
101 finance2026-03-11 23:24:50
Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
Finviz2026-03-11 23:24:50
Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Finviz2026-03-12 12:03:53
Theriva Biologics Reports Full-Year 2025 Operational Highlights and Financial Results
Finviz2026-03-12 12:03:53
SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009
Finviz2026-03-12 12:40:00
Is Bristol Myers' Extensive Pipeline the Secret to Its Future Expansion?
101 finance2026-03-12 17:19:00
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Finviz2026-03-12 20:06:49
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Finviz2026-03-12 20:06:49
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results
Finviz2026-03-12 20:09:50
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer
Finviz2026-03-09 11:03:47
Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough
Finviz2026-03-09 11:33:52
The epilepsy treatment drug developed by Xenon Pharmaceuticals (XENE) successfully met the primary endpoint in a pivotal Phase III clinical trial, a breakthrough that drove its share price up by 16.5% in pre-market trading.
老虎证券2026-03-09 12:00:04
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
Finviz2026-03-09 12:03:10
Bristol-Myers Squibb Shares Edge Up 0.56% on Pipeline Progress as 660M Volume Ranks 216th in Market Activity
101 finance2026-03-09 23:30:46
C4 Therapeutics (CCCC) Well Positioned With Cemsidomide Trial Data
Finviz2026-03-10 00:13:04
Johnson & Johnson (JNJ) Announces the FDA Approval of TECVAYLI plus DARZALEX FASPRO
Finviz2026-03-10 08:40:20
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Finviz2026-03-10 11:07:14
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
Finviz2026-03-11 11:03:53
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
Finviz2026-03-11 12:03:49
Northstrive Fund II has sent a letter to the Board of Directors of Bluejay Diagnostics Inc, recommending that they carefully evaluate a potential acquisition opportunity.
老虎证券2026-03-11 13:48:56
BMY Slides to 206th in Trading Volume Amid Clinical Wins and Earnings Pressures
101 finance2026-03-11 23:24:50
Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
Finviz2026-03-11 23:24:50
Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Finviz2026-03-12 12:03:53
Theriva Biologics Reports Full-Year 2025 Operational Highlights and Financial Results
Finviz2026-03-12 12:03:53
SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009
Finviz2026-03-12 12:40:00
Is Bristol Myers' Extensive Pipeline the Secret to Its Future Expansion?
101 finance2026-03-12 17:19:00
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Finviz2026-03-12 20:06:49
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Finviz2026-03-12 20:06:49
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results
Finviz2026-03-12 20:09:50
REFRACTORY stock price change
On the last trading day, REFRACTORY stock closed at 37.80 INR, with a price change of 0.80% for the day.
Trade stock perpsREFRACTORY stock detailsAbout Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more